Form 8-K · Current Report · Filed 2025-02-26
AbbVie Inc. Completes Senior Notes Offering
On February 26, 2025, AbbVie Inc. completed its previously announced underwritten public offering of senior notes totaling $3.0 billion in aggregate principal amount. The offering included 4.650% senior notes due 2028, 4.875% senior notes due 2030, 5.200% senior notes due 2035, and 5.600% senior notes due 2055. The notes are governed by an indenture and are unsecured, unsubordinated obligations of AbbVie. The transaction was registered under the Securities Act of 1933 and further described in AbbVie's prospectus supplement. The legal documents related to the offering are provided as exhibits to this Form 8-K.
- Filer
- AbbVie Inc. ABBV · NYSE
- Filed
- Accession
- 0001104659-25-017490
- CIK
- 0001551152
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Other Events
Financial Statements and Exhibits
Market reaction
Close before filing
$204.14
Next session
+0.4%
Since filing
+22.9%
Latest close
$250.94
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ABBV reporting the same item, with the next session's move:
Exhibits (2)
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Never miss another ABBV filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.